Details for Patent: 8,865,937

Which drugs does patent 8,865,937 protect, and when does it expire?

Patent 8,865,937 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 8,865,937

Title:	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
Abstract:	The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
Inventor(s):	Dedhiya; Mahendra G. (Pomona, NY), Surana; Rahul (Commack, NY)
Assignee:
Application Number:	12/941,293
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,865,937
Patent Claim Types: see list of patent claims	Compound; Composition; Dosage form; Process;

Drugs Protected by US Patent 8,865,937

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013	AB	RX	Yes	No			Y	Y
Allergan	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013	AB	RX	Yes	No			Y	Y
Allergan	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-003	Jul 25, 2013	AB	RX	Yes	No			Y	Y
Allergan	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-004	Jul 25, 2013	AB	RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,865,937

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2779711
Canada	2790933
European Patent Office	2496079
European Patent Office	2536688
Japan	2013510176